by Jordana Choucair | Mar 2, 2022 | Life Sciences
The National Institutes of Health ordered a major review of federal biosecurity policies for experiments involving potentially dangerous pathogens. The agency hopes to gather recommendations by the end of 2022 on where to draw the line on potentially risky research....
by Jordana Choucair | Mar 1, 2022 | Life Sciences
A large new dataset indicates that Pfizer Inc.-BioNTech SE’s COVID-19 vaccine is much less effective for children ages 5 to 11 than it is for older people. According to researchers and federal officials who reviewed the data, the drop in performance may be...
by Jordana Choucair | Mar 1, 2022 | Life Sciences
The U.S. Patent and Trademark Office ruled that the Broad Institute of MIT and Harvard owns the rights to the genome editing technology CRISPR. The decision invalidates patent rights UC Berkeley granted gene-editing companies developing human therapies. It also means...
by Jordana Choucair | Feb 28, 2022 | Life Sciences
Two small biotech companies sued Moderna Inc. on claims that it infringed on their patent rights for a technology they said was key to Moderna developing its mRNA vaccine for COVID-19. Moderna has said it expects vaccine sales to top $19 billion in 2022.The two...
by Jordana Choucair | Feb 28, 2022 | Life Sciences
Drugmaker Viatris Inc., formerly known as Mylan NV, will pay $264 million to settle a class-action lawsuit alleging it engaged in anticompetitive behavior to delay generic competition to its EpiPen allergy treatment. The litigation has been ongoing for years,...
by Jordana Choucair | Feb 24, 2022 | Life Sciences
Sanofi and GSK said they plan to submit their COVID-19 vaccine for authorization to the FDA and the European Medicines Agency. Two doses of the vaccine had 100 percent efficacy against severe disease and hospitalization. Efficacy against any infection at all was 57.9...
Recent Comments